⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SRZN News
Surrozen, Inc. Common
Form 8-K
sec.gov
SRZN
Surrozen Reports Third Quarter 2026 Financial Results and Provides Business Update
globenewswire.com
SRZN
Surrozen to Present at Upcoming Healthcare Investor Conference
globenewswire.com
SRZN
Form 8-K
sec.gov
SRZN
Surrozen Announces Closing of Second Tranche of March 2025 Private Placement for $95.1 Million
globenewswire.com
SRZN
Form 8-K
sec.gov
SRZN
Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema
globenewswire.com
SRZN
Surrozen Announces Submission of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema
globenewswire.com
SRZN
Surrozen to Present at Upcoming Healthcare Investor Conferences
globenewswire.com
SRZN
Form 8-K
sec.gov
SRZNW
SRZN